#ESCCongress – [Not Published Yet] Randomized Trial: SGLT2 inhibitors Seems Beneficial for Heart Failure Even in Nondiabetics

Commentaries: Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction – DAPA-HF – American College of Cardiology (free) Dapagliflozin reduces death and hospitalisation in patients with heart failure – European Society of Cardiology (free)

Related Commentary on Twitter

DAPA-HF trial at #ESCCongress: significant reduction of events in HFrEF patients by dapagliflozine. Half of the 5744 pts had diabetes, the others did not: same effect in both groups.
SGLT2 inhibitors just better diuretics or the "statins of HF"?@escardio #cardiotwitter pic.twitter.com/nzTv58d0cd

— Stephan Achenbach (@Steph_Achenbach) September 1, 2019